Roche and the ABPI: What Does it Mean for Self-Regulation?
This article was originally published in SRA
Executive Summary
Roche's decision not to rejoin the UK industry body the ABPI after its six-month suspension for breaching the advertising code of practice has understandably made waves in the sector. After all, Roche is a pillar of the pharmaceutical establishment and its departure will affect both the ABPI's image and its revenues. But are there any implications for the future of self-regulation by the industry, as some have suggested?
You may also be interested in...
Roche Rejoins ABPI After Long Absence To Help Forum Address Brexit
Roche's decision to return to the UK industry body the ABPI reflects the Swiss company’s considerable commercial interests in Britain and the need for drug makers operating there to work more closely together as the Brexit process begins.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.